Abstract

Background

Trelagliptin and vildagliptin are oral dipeptidyl peptidase-4 (DPP-4) inhibitors used in the treatment of type 2 diabetes mellitus. The administration of vildagliptin is twice daily, whereas trelagliptin provides the convenience of once-weekly dosing, which may enhance patient adherence. A phase 3 clinical trial was conducted to assess the non-inferiority of trelagliptin compared to vildagliptin.

Methods

This multicenter, randomized, open-label, parallel-group, active-controlled non-inferiority clinical trial was conducted at 10 geographically distinct sites across India. A total of 240 treatment-naive patients with type 2 diabetes mellitus were randomized in a 1:1 ratio to receive either trelagliptin (100 mg once weekly) or vildagliptin (50 mg twice daily) for 16 weeks. The primary endpoint was non-inferiority of trelagliptin to vildagliptin in reducing glycated hemoglobin (HbA1c) levels from baseline to week 16. Secondary efficacy measures included changes in fasting and postprandial blood glucose, fasting insulin, glucagon, C-peptide, and glucagon-like peptide-1 (GLP-1) levels. Safety was assessed based on the incidence of adverse events.

Results

At week 16, the mean HbA1c levels were 7.18 ± 1.47% and 7.21 ± 1.49% in trelagliptin and vildagliptin groups, respectively (Δ -0.89% vs. Δ -1.00%, p < 0.0001). The difference between groups was 0.11% (95% CI: -0.28 to 0.50; p = 0.5899), showing non-inferiority of trelagliptin. A total of 48.57% of patients in the trelagliptin group and 47.57% in the vildagliptin group achieved the target HbA1c level of <7% (p = 0.8850). No statistically significant differences were observed between the groups for glycemic parameters, including fasting blood glucose (Δ 1.11; 95% CI: -16.79 to 19.02; p = 0.9025), 2-hr postprandial glucose (Δ 3.33; 95% CI: -30.55 to 23.88; p = 0.8093), fasting serum insulin (Δ 5.22; 95% CI: -15.01 to 25.45; p = 0.6113), fasting glucagon (Δ 0.72; 95% CI: -96.34 to 94.90; p = 0.9882), C-peptide (Δ 0.36; 95% CI: -0.31 to 1.03; p = 0.2912), and GLP-1 levels (Δ -0.02; 95% CI: -0.06 to 0.02; p = 0.3995). All reported adverse events were mild in nature and resolved without any lasting effects. Adverse events occurred in 6.67% (8/120) of patients in the trelagliptin group and 9.17% (11/120) in the vildagliptin group.

Conclusions

Trelagliptin showed a significant reduction in HbA1c, fasting, and postprandial glucose levels, indicating effective glycemic control in patients with type 2 diabetes mellitus. The study drug exhibited a favorable safety profile, with no major adverse events reported. Overall, trelagliptin proved to be both efficacious and well-tolerated, demonstrating non-inferiority to vildagliptin.

Plecasoft contains the active ingredient plecanatide, which works directly in the intestine to help increase fluid and support regular bowel movements. It acts like a natural substance in your body to draw water into the intestines, making stools softer and easier to pass. This makes stools softer and easier to pass. It helps relieve symptoms like hard stools, bloating, and stomach discomfort. Plecasoft is used in adults to treat long-term(chronic) constipation and constipation caused by irritable bowel syndrome (IBS-C).

The combination of ‘Pregabalin and Duloxetine’ is an emerging, fast-growing therapy for Painful Peripheral Neuropathy associated with Mood Disorders. Upnuron-D, offers enhanced efficacy in relieving neuropathic pain while helping regulate mood. Upnuron-D, provides patients with effective pain relief and mood stabilization, promoting overall well-being.

Topical Pregabalin 8% is an emerging therapy for Diabetic Neuropathic Pain. This targeted formulation is designed to reduce pain while minimizing adverse effects. Reperi Gel, provides patients with an effective solution that manages discomfort and minimizes systemic side effects, helping them lead a more comfortable life.

Bevon-NH is a comprehensive blend of essential multi-vitamins, minerals, and antioxidants formulated to ensure well-being of Nerve Health. Bevon-NH, helps alleviate symptoms of Nutritional Deficiency & Diabetic/ Peripheral Neuropathy. By addressing Nerve-related discomfort, Bevon-NH not only relieves pain but also promotes holistic wellness.